Ginkgo biloba effects in the treatment of patients with chronic schizophrenia treated with Risperidone in Joneghan Sinai Hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138903192085N3

Enrollment

Registered

2010-06-09

Start date

2009-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Routine treatment plus 4mg risperidone three times daily and Ginkgo biloba tablet in three doses of 80 mg daily (240 mg) for 12 weeks. Intervention 2: Routine treatment and 4mg risperi

Treatment - Drugs

Placebo

Routine treatment plus 4mg risperidone three times daily and Ginkgo biloba tablet in three doses of 80 mg daily (240 mg) for 12 weeks.

Routine treatment and 4mg risperidone three times daily and placebo for 12 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Schizophrenia diagnosis Exclusion criteria: Use of other herbal medicines, aspirin or anticoagulant drugs, clotting problems before and during treatment with Ginkgo

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Improve positive and negative signs. Timepoint: at the begining, 2, 4, 6, 8, 12 weeks after treatment and one month after end of treatment. Method of measurement: complete Anderson positive and negative questionnaire.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026